Scholarlink

<p>Psoriasis is a chronic immune-driven inflammatory condition that affects millions of people worldwide. Biologics appeared in the recent years to offer an effective treatment for moderate-to-severe plaque psoriasis. Their efficacy, however, is influenced by patient characteristics, such as obesity, disease severity or prior failure to biologic therapy. This review focuses on the current management of moderate-to-severe plaque psoriasis using tildrakizumab, the only interleukin-23p19 inhibitor offering two dosing options (100&#xa0;mg or 200&#xa0;mg) according to individual patient characteristics (high disease burden/body weight). It examines clinical data on the efficacy and effectiveness of both doses and identifies patient profiles that benefit most from tildrakizumab 100&#xa0;mg or 200&#xa0;mg. The manuscript also presents practical recommendations to help dermatologists individualize treatment, particularly guiding the appropriate use of the 200&#xa0;mg dose in routine clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimizing Psoriasis Treatment with Tildrakizumab: Current Evidence and Expert Recommendations for Treatment Individualization in Clinical Practice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月11日

查看全文
  • Ricardo Ruiz-Villaverde,
  • Almudena Mateu,
  • Pedro Mendes-Bastos,
  • Tiago Torres

摘要

Psoriasis is a chronic immune-driven inflammatory condition that affects millions of people worldwide. Biologics appeared in the recent years to offer an effective treatment for moderate-to-severe plaque psoriasis. Their efficacy, however, is influenced by patient characteristics, such as obesity, disease severity or prior failure to biologic therapy. This review focuses on the current management of moderate-to-severe plaque psoriasis using tildrakizumab, the only interleukin-23p19 inhibitor offering two dosing options (100 mg or 200 mg) according to individual patient characteristics (high disease burden/body weight). It examines clinical data on the efficacy and effectiveness of both doses and identifies patient profiles that benefit most from tildrakizumab 100 mg or 200 mg. The manuscript also presents practical recommendations to help dermatologists individualize treatment, particularly guiding the appropriate use of the 200 mg dose in routine clinical practice.